AMAG Must Build Market For Approved Female Libido Drug To Avoid Addyi’s Fate

AMAG Pharmaceutical’s HSDD drug Vyleesi, has been approved by the FDA. But analysts warn it must build the market in women who may not be aware they have a condition if it is to fare better than Sprout’s Addyi.

Megaphone
AMAG plans to create and reach a market that may not be aware they have a condition • Source: Shutterstock

More from New Products

More from Scrip